Natera, Inc. (NTRA)

Market Cap	20.91B
Revenue (ttm)	1.70B
Net Income (ttm)	-190.43M
Shares Out	135.19M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,044,330
Open	153.12
Previous Close	153.83
Day's Range	152.35 - 155.64
52-Week Range	83.13 - 183.00
Beta	1.80
Analysts	Strong Buy
Price Target	179.00 (+15.72%)
Earnings Date	May 8, 2025

About NTRA

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 4,434
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA
• Website: https://www.natera.com

Financial Performance

In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.

Analyst Forecast

According to 17 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price forecast is $179.0, which is an increase of 15.72% from the latest price.

Price Target

$179.0

(15.72% upside)

Analyst Consensus: Strong Buy